Replimune Receives Approval to Launch Tudriqev in the US for Melanoma
MT newswire2026/10/01 20:33Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
04:33 PM EDT, 10/01/2026 (MT Newswires) -- Replimune (REPL) said late Thursday its Tudriqev to treat unresectable advanced cutaneous melanoma is now commercially available in the US. The indication is authorized under accelerated approval from the US Food and Drug Administration in early August based on trial objective response rate and response duration, according to a statement.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Silver Price Forecast: Fresh yearly low puts $50 in bears’ sight
FXStreet•2026/10/23 19:00
Philippine Peso: Bearish but constrained by Oil – OCBC
FXStreet•2026/10/23 18:57
Turkish Lira: CBRT maintains cautious easing stance - Commerzbank
FXStreet•2026/10/23 18:00
BUZZ-Republic Bancorp shares fall as Q3 profit misses expectations
路透社•2026/10/23 17:31
Crypto prices
More
Bitcoin
BTC
$81,392.05
+0.15%
Ethereum
ETH
$2,400.61
+0.81%
Tether USDt
USDT
$0.9988
+0.01%
BNB
BNB
$743.27
+1.98%
XRP
XRP
$1.31
+0.20%
USDC
USDC
$0.9999
+0.01%
Solana
SOL
$104
+0.39%
TRON
TRX
$0.3297
+0.61%
Zcash
ZEC
$1,238.83
+1.67%
Hyperliquid
HYPE
$77.77
+0.05%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now